SuperMeat

CollPlant is a regenerative medicine company that focuses on 3D bioprinting of tissues and organs and also develops and commercializes tissue repair products for orthobiologics. The company's products are based on the rhCollagen that is produced with CollPlant’s proprietary plant-based genetic engineering technology. The rhCollagen BioInk is ideal for 3D bioprinting of tissues and organs, and the unique Vergenix line of rhCollagen products contains a soft tissue repair matrix for treating tendinopathy and a wound repair matrix to promote rapid optimal healing of acute and chronic wounds. CollPlant is headquartered in Rehovot, Israel.

Magdent’s novel technology utilizes electromagnetic fields, PEMF technology, to stimulate, accelerate, and improve bone formation and enable shorter and more successful healing of bone and soft tissue in events such as a fracture or dental implant. Magdent’s solutions are high usability medical devices that incorporate a battery, electronic modules, and a coil. The orthopedic device is a thin lightweight silicon patch, placed over the fracture either under the case or over the skin while the dental device is shaped like a healing abutment.

Brevel has created an innovative method of cultivating microalgae that is both sustainable and cost-effective, while also producing high-quality output for a range of markets that have yet to be explored. This technology utilizes advanced indoor systems that are sterile and fully automated, with intense internal illumination. As a result, Brevel has achieved remarkable results, including a cost reduction of over 90% and yields that are up to 200 times higher than existing alternatives. Leveraging these production capabilities, Brevel is now venturing into various markets that require products derived from microalgae.

RedHill Biopharma Ltd. (NASDAQ: RDHL) is a specialty biopharmaceutical company primarily focused on gastrointestinal diseases and infectious diseases. RedHill’s U.S. commercial operations, headquartered in Raleigh, NC, include a gastrointestinal-focused sales force promoting several specialty gastrointestinal products in the U.S. RedHill’s pipeline includes several drug candidates in advanced clinical development stages addressing clear medical needs and aiming to relieve suffering and save lives. RedHill’s drugs are largely de-risked and are potentially of lower cost and faster to market than new chemical entities under development. RedHill’s products are based on several technology platforms and address several disease targets, thus providing for risk diversification. RedHill’s experienced management team, board of directors and advisory board, based in Israel, the U.S., Canada and Europe, comes with a successful track record of bringing patented drugs to the market, as well as extensive managerial, financial, and transactional expertise.

Regentis Biomaterials is a privately held company focused on developing and commercializing proprietary hydrogels for tissue regeneration. The company’s core technology is a iodegradable hydrogel called Gelrin™. It is based on polyethylene glycol diacrylate and denatured fibrinogen originally developed at the Technion University by Dr. Dror Seliktar. The Gelrin hydrogel platform combines the stability and versatility of a synthetic material with the bio-functionality of a natural substance for a range of clinical applications and has undergone extensive preclinical and safety testing over the last few years. The company’s flagship product, GelrinC™,designed for the treatment of articular cartilage lesions, is currently in clinical trials.

IceCure Medical is a medical device company setting new standards in minimally-invasive tumor therapy for women’s health and interventional oncology. Founded in 2006 to advance the treatment of cancerous tumors, IceCure’s core technology is based on cryoablation. Its proprietary third-generation technology uses freezing temperatures (liquid nitrogen) to effectively destroy tumors safely, quickly, and painlessly, without the need for surgery. Commercially available in the U.S.A., Europe, Hong-Kong, Thailand, Singapore and South- Central America, its flagship system, ProSense™, uses ultrasound imaging to guide a small probe (thin hollow needle) into the tumor. The easy-to-use ProSense™ cryoablation procedure enables full physician control and can be performed in less than 30 minutes in the comfort of a doctor’s office. As a proven solution for the treatment of fibroadenomas (benign breast tumors), the ProSense system is also indicated for use in the fields of general surgery, oncology, gynecology and urology.

Splisense is develops antisense oligonucleotide based therapies to target genetic diseases caused by splicing mutations. The company has developed a compound to cure the lung disease in cystic fibrosis patients carrying a specific splicing mutation. It is also developing a targeted modulation approach to correct the splicing pattern of CFTR transcripts according to the specific mutation carried.

Phytolon is transforming the process of creating food colors by using an innovative and environmentally friendly technology. This allows them to produce top-notch, healthy food colors at an affordable price. Phytolon's goal is to utilize scientific progress to improve human health while also ensuring sustainability for the environment.

BlueWind Medical develops and markets a wireless neurostimulation device for the treatment of peripheral neuropathic pain (PNP).

ECOncrete technology provides sustainable solutions for construction of ecologically active infrastructures, in the coastal and marine environment as well as other urban landscapes. The Company develops, produces and supports implementation of innovative concrete products designed for enhancing the biological and ecological value of coastal and marine infrastructures. ECOncrete's unique biological traits encourage biogenic buildup. They also provide substantial structural and economic advantages in terms of increased stability and longevity, as well as a reduction in maintenance costs.

MSICS Pharma is a pharmaceutical company that manufactures and produce naturally-sourced Psilocybin for medical purpose.

NeuroSense Therapeutics Ltd., is a clinical-stage biotechnology company, dedicated to the discovery and development of treatments for debilitating neurodegenerative diseases. Its lead product, PrimeC, is a novel oral therapy for the treatment of amyotrophic lateral sclerosis (ALS). The company's preclinical pipeline includes: (1) StabiliC for the treatment of Parkinson's disease and (2) CogniC for the treatment of Alzheimer's disease. NeuroSense Therapeutics Ltd. was incorporated in 2017 and is headquartered in Herzliya, Israel.